| Title |
Pegylated liposomal doxorubicin in malignant pleural mesothelioma: a possible guardian for long-term survival
|
|---|---|
| Published in |
OncoTargets and therapy, September 2012
|
| DOI | 10.2147/ott.s36915 |
| Pubmed ID | |
| Authors |
Paul Zarogoulidis, Maria Mavroudi, Konstantinos Porpodis, Kalliopi Domvri, Antonios Sakkas, Nikolaos Machairiotis, Aikaterini Stylianaki, Anastasios Tsiotsios, Nikolaos Courcoutsakis, Konstantinos Zarogoulidis |
| Abstract |
Malignant pleural mesothelioma is a rare and aggressive malignancy of the pleura correlated with exposure to asbestos, with a medium survival of 11-12 months after diagnosis. A case of a 67-year-old male who had previously worked in the asbestos industry and is a current smoker is reported. The computed tomography evaluation revealed a right pleural mass with pleural thickening, and the pleural biopsy confirmed a diagnosis of malignant pleural mesothelioma. He was treated with chemotherapy consisting of etoposide, paclitaxel, and pegylated liposomal doxorubicin hydrochloride. After completion of chemotherapy, radiologic evaluation confirmed a reduction of pleural thickening and improvement in his symptoms. A complete presentation of each drug formulation and characteristics are also included in this paper. The patient's follow-up is continuing, and computed tomography reveals stable disease 9 years after initial examination. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 50% |
| Practitioners (doctors, other healthcare professionals) | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 9 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 9 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 3 | 33% |
| Student > Bachelor | 1 | 11% |
| Student > Postgraduate | 1 | 11% |
| Unknown | 4 | 44% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 3 | 33% |
| Immunology and Microbiology | 1 | 11% |
| Agricultural and Biological Sciences | 1 | 11% |
| Unknown | 4 | 44% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 November 2012.
All research outputs
#15,305,492
of 25,584,565 outputs
Outputs from OncoTargets and therapy
#785
of 2,967 outputs
Outputs of similar age
#111,102
of 188,508 outputs
Outputs of similar age from OncoTargets and therapy
#7
of 12 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. This one is in the 38th percentile – i.e., 38% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,967 research outputs from this source. They receive a mean Attention Score of 3.0. This one has gotten more attention than average, scoring higher than 71% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 188,508 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 39th percentile – i.e., 39% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 12 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 50% of its contemporaries.